We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Genetic Analysis System Will Use Nanoscale Whole Genome Imaging Technology

By Biotechdaily staff writers
Posted on 13 Nov 2007
Nanoscale whole genome imaging and analytic platforms are being developed for applications in clinical genetics, cancer diagnostics, and other biomedical applications. More...
Nanosystems technology provides fast, comprehensive, and low-cost analysis of genomic, epigenomic, and proteomic information with sensitivity at the single cell/single molecule level.

Agilent Technologies Inc. (Santa Clara, CA, USA) and BioNanomatrix Inc. (Philadelphia, PA, USA) have entered into a collaboration to develop a genetic analysis system. BioNanomatrix is developing technology that enables nanoscale single molecule identification and analysis of the entire genome, delivering single-molecule sensitivity in a highly parallel format. Agilent will provide the measurement instrumentation platform for the system.

BioNanomatrix's analytic platform has the potential to provide rapid, comprehensive, and cost-effective ultra-high resolution analyses of DNA. The two companies intend to collaborate closely in the development of an integrated system and applications.

"BioNanomatrix's unique nanoscale whole genome imaging and analysis technology, with sensitivity at the level of the single molecule, has the potential to enable a number of important new applications for life-sciences research and clinical medicine,” said Nick Roelofs, vice president and general manager of the life-sciences solutions unit at Agilent.

Dr. Michael Boyce-Jacino, CEO of BioNanomatrix said, "We now have a partner with strong life sciences expertise and capabilities committed to working with us to develop key life- sciences applications, such as assays for genotoxicity and cytogenetics, as well as potentially DNA sequencing.”


Related Links:
Agilent
BioNanomatrix

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image

Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings

Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.